Editor's Note:This Week's Bullish Stocks in Hong Kong and USAThe column closely follows market trends every week, reviewing the weekly performance of Hong Kong and US stock markets, helping mooers to sort out the week's hot sectors, strong stocks, and significant news, looking for investment themes with profit potential.
This week,$Hang Seng Index (800000.HK)$it has increased by a total of 1.1%, closing at 23601.26 points; during the same period$Hang Seng TECH Index (800700.HK)$it has decreased by a total of 0.65%, closing at 5246.87 points; $Hang Seng China Enterprises Index (800100.HK)$During the same period, it has accumulated an increase of 1.36%, closing at 8583.86 points.
In terms of Sectors and individual Stocks, the Hong Kong pharmaceutical Sector is performing strongly, among which$3SBIO (01530.HK)$ranked first on the weekly growth list, with a cumulative increase of 57.38% this week, and the stock price has reached a new high in many years;$REMEGEN (09995.HK)$the stock surged by 27% and ranked fifth on the weekly growth list; additionally, $CMS (00867.HK)$It also recorded a 24% increase.
CICC published a research report stating that$3SBIO (01530.HK)$will grant$Pfizer (PFE.US)$exclusive rights for the development, production, and commercialization of PD-1/VEGF bispecific antibody (SSGJ-707) outside of China. Pfizer will receive commercialization options for the Chinese market. The firm maintains its adjusted earnings forecast for 3SBIO for the next two years at 2.41 billion and 2.6 billion yuan respectively, reiterating the "outperform" rating and raising the target price by 56.3% to 21.1 Hong Kong dollars.
Several innovative drug companies will showcase innovative drug research results at the 2025 American Society of Clinical Oncology (ASCO) annual meeting from May 30 to June 3. Analysts also believe that benefited from$3SBIO (01530.HK)$with$Pfizer (PFE.US)$The news of global equity cooperation for the PPD-1/VEGF dual antibody SSGJ-707 is driving Chinese innovative pharmaceutical companies to accelerate their integration into the global Industry Chain through technology licensing, enhancing market expectations for domestically produced innovative drugs to go global.
Guoyuan Securities pointed out that Chinese innovative drugs are entering a phase of harvesting results, with continuous favorable R&D progress that is not affected by the 'trade war,' and is expected to continue leading investments in the pharmaceutical Sector by 2025. China Aviation Securities stated that as the process of domestic innovative pharmaceutical companies going global accelerates, the investment value of domestically produced innovative drug sectors becomes prominent, leading to profound changes in the Industry, enhanced competitiveness of enterprises, and emerging on the international stage, as well as rapid development in domestic innovative drug R&D with outstanding related data performance in 2024.
The A-share 'top students' are successively listed in Hong Kong, led by the power Battery giants.$CATL (03750.HK)$Raising 35.657 billion makes it the largest IPO in the Hong Kong stock market!$HENGRUI PHARMA (01276.HK)$The fixed price is HKD 44.05 per share, with an oversubscription of 454 times.
Contemporary Amperex Technology's H shares were listed on May 20, achieving an almost record listing speed in recent years, taking just over three months from filing on February 11 to listing. This Hong Kong IPO raised HKD 35.657 billion, making it the largest IPO project in the Hong Kong market. The cornerstone investors include well-known institutions such as Hillhouse Capital, Gaoling Asset Management, the Kuwait Investment Authority, and Royal Bank of Canada.
$CATL (03750.HK)$After listing, the stock price performed strongly, with a cumulative increase of over 22% this week. As of May 23, the closing price of Contemporary Amperex Technology's H shares was HKD 322.4 (approximately CNY 296.59), while the A-share price was CNY 266.99, indicating a premium of about 11% for the Hong Kong shares over the A shares.
Hengrui Pharmaceuticals, founded in 1970, was listed on the Shanghai Stock Exchange in 2000. It is an innovative international pharmaceutical company that focuses on the research, production, and promotion of high-quality medicines. The company specializes in new drug development in areas such as oncology, metabolism, cardiovascular diseases, immunology, respiratory system diseases, and neuroscience, making it one of the most innovative pharmaceutical leaders in China.
$HENGRUI PHARMA (01276.HK)$This Friday, it was listed in Hong Kong, priced at the upper end of the issuance price range at HKD 44.05 per share. During the public offering phase, Hengrui Pharmaceuticals received an oversubscription of 454.85 times, with an intra-day gain of over 37%. At one point, it even erased the price difference with its A shares. By the close on May 23, the increase exceeded 25%.
$ALI PICTURES (01060.HK)$A weekly increase of 55.56%, the stock price has reached a three-year high! Citigroup states that the potential of IP Commodities has not yet been fully realized.
On May 21, $ALI PICTURES (01060.HK)$It was announced that the company plans to change its name to DAMAI Entertainment. The Board of Directors believes that changing the company name will benefit the company in further enhancing its brand market awareness and reshaping its brand strategy in the entire entertainment ecosystem, especially in the offline entertainment market, while providing a more relevant and unique corporate image and identity; it will also be beneficial for the group’s future diversified Business development, offering consumers a higher quality comprehensive entertainment experience across all tracks of the entertainment industry.
Citigroup stated that the management of ALI PICTURES indicated during the Earnings Conference that film investments will remain prudent over the next 2-3 years, while focusing human resources on the DAMAI business and IP Commodity sales Sector. Based on this, Citigroup has adjusted its Target Price from HKD 0.75 to HKD 0.92 and reiterated its ‘Buy’ rating. Citigroup also pointed out that important IPs such as ‘Chiikawa’ and ‘Crayon Shin-chan’ can bring additional revenue in the new fiscal year, and their current valuation does not fully reflect the growth potential of IP derivative business.
On the other hand, the stocks that performed weakly this week are as follows:
Editor/melody
